Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

To join this study, you would need to have been diagnosed with type 2 diabetes. You should also have a body mass index (BMI) of 27 or higher, which means you are considered overweight or have obesity. Your diabetes treatment, which could be diet and exercise alone or with tablets (but not a specific type called DPP-4 inhibitors), must have been stable for at least three months. If you haven't been on medication yet, and your average blood sugar level (HbA1c) is between 6.5% and 7.5%, you might still be able to join. You'd also need to have tried to lose weight through diet and/or exercise in the last six months without success.

There are also some reasons why you might not be able to join. For example, if you have type 1 diabetes, have had severe low blood sugar or diabetes-related emergencies recently, or if you've recently started certain medications that can affect your weight. Other reasons include a history of certain cancers (like medullary thyroid cancer or specific family conditions), uncontrolled high blood pressure, unstable heart problems, or issues with your pancreas or digestive system. If you've had certain mental health conditions, like a recent suicide attempt or severe depression, or if you're currently taking other weight-loss medications or injections for diabetes like semaglutide or tirzepatide, you also wouldn't be able to participate.

If you decide to take part in this study, you would receive either the new medicine, Ribupatide, or a placebo (an inactive substance that looks just like the medicine). You wouldn't know which one you are getting. Both are given as injections under the skin once a week. You would have regular visits to the clinic for health checks, blood tests, and to measure your weight and blood sugar levels. The study involves ongoing follow-up to monitor your health and how you respond to the treatment. The total duration of the study would be explained to you, including the different stages of treatment and monitoring.